← Back to Disclosure
Disclosure By Michelle G. · Nov 13, 2026

Ethics Group Calls for Investigation into Health Official Over Potential Conflict of Interest in Hormone Therapy Policy

A nonpartisan watchdog group has requested an investigation into Alicia Jackson, the director of the Advanced Research Projects Agency for Health within the Department of Health and Human Services (HHS), over alleged ethics violations related to her involvement in hormone replacement therapy policy changes. The Campaign Legal Center filed a letter with HHS's inspector general detailing concerns about Jackson’s financial interests that may have influenced her actions.

Jackson was instrumental in advocating for federal health policy updates regarding hormone replacement therapies, which include the removal of “black box warnings” from these treatments. However, at the time she made public statements supporting this change, she owned significant stock in Evernow, a company providing access to menopause-related hormone treatments. According to her financial disclosures, Jackson held at least $115,000 worth of Evernow shares and an unspecified amount of stock options.

The Campaign Legal Center’s letter also points out that Jackson did not properly disclose up to $400 million in underlying assets managed by her husband's investment firm, potentially adding another layer of conflict. Additionally, the watchdog group identified investments in a second company offering hormone treatments for menopause, further complicating potential conflicts of interest.

Jackson was placed on administrative leave recently, although HHS has not provided an official reason for this action. Her role involves overseeing taxpayer-funded medical technology and research initiatives at the Advanced Research Projects Agency for Health. The timing of her leave coincides with increasing scrutiny over her financial interests and public statements regarding hormone therapy policy changes.

The controversy surrounding Jackson’s actions highlights broader concerns about transparency in government decision-making processes, particularly when it comes to health policies that can significantly impact patient care and treatment options. Critics argue that her endorsement of the policy change while holding stock in a company benefiting from such changes raises serious questions about ethical conduct and potential misuse of public office for personal gain.

This case underscores the importance of stringent conflict-of-interest regulations within federal agencies, especially those dealing with healthcare policies that can affect millions of Americans. The Campaign Legal Center’s call for an investigation aims to ensure accountability and maintain public trust in government officials responsible for shaping health policy.

← Back to Disclosure